WHO. Global Priority list of antibiotic-resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. 348–65. WHO. 2017;348–365.

Verdugo-Paiva F, Otaiza F, Roson-Rodriguez P, Rojas-Gomez AM, Galas M, El Omeiri N et al. Effects of screening strategies to detect carbapenem-resistant gram-negative bacteria: a systematic review. Am J Infect Control 2022https://doi.org/10.1016/j.ajic.2022.02.018

Perovic O, Ismail H, Quan V, Bamford C, Nana T, Chibabhai V, et al. Carbapenem-resistant Enterobacteriaceae in patients with bacteraemia at tertiary hospitals in South Africa, 2015 to 2018. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clin Microbiol. 2020;39(7):1287–94. https://doi.org/10.1007/s10096-020-03845-4

Article  CAS  Google Scholar 

Chang SL, Dela Cruz CS, Zhang D, Clinical, Epidemiology. Risk factors, and control strategies of Klebsiella pneumoniae infection. Front Microbiol. 2021;12:750662. https://doi.org/10.3389/fmicb.2021.750662

Article  PubMed  PubMed Central  Google Scholar 

Wang M, Earley M, Chen L, Hanson BM, Yu Y, Liu Z, et al. Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. Lancet Infect Dis. 2022;22(3):401–12. https://doi.org/10.1016/s1473-3099(21)00399-6

Article  CAS  PubMed  Google Scholar 

Qu J, Qi TT, Qu Q, Long WM, Chen Y, Luo Y, et al. Polymyxin B-Based regimens for patients infected with carbapenem-resistant gram-negative Bacteria: clinical and microbiological efficacy, mortality, and Safety. Infect Drug Resist. 2022;15:1205–18. https://doi.org/10.2147/IDR.S357746

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen HY, Jean SS, Lee YL, Lu MC, Ko WC, Liu PY, et al. Carbapenem-Resistant enterobacterales in Long-Term Care facilities: A Global and Narrative Review. Front Cell Infect Microbiol. 2021;11:601968. https://doi.org/10.3389/fcimb.2021.601968

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stone GG, Newell P, Bradford PA. In Vitro Activity of Ceftazidime-Avibactam against isolates from patients in a phase 3 clinical trial for treatment of complicated intra-abdominal infections. Antimicrob Agents Chemother. 2018;62. https://doi.org/10.1128/AAC.02584-17

Matesanz M, Mensa J, Ceftazidime-avibactam. Rev Esp Quimioter. 2021;34(Suppl 1):38–40. https://doi.org/10.37201/req/s01.11.2021

Article  PubMed  PubMed Central  Google Scholar 

Zheng G, Cai J, Zhang L, Chen D, Wang L, Qiu Y, et al. Ceftazidime/Avibactam-Based Versus Polymyxin B-Based therapeutic regimens for the treatment of Carbapenem-resistant Klebsiella pneumoniae infection in critically ill patients: a retrospective cohort study. Infect Dis Ther. 2022. https://doi.org/10.1007/s40121-022-00682-0

Article  PubMed  PubMed Central  Google Scholar 

Fang J, Li H, Zhang M, Shi G, Liu M, Wang Y, et al. Efficacy of Ceftazidime-Avibactam Versus Polymyxin B and Risk factors affecting clinical outcomes in patients with carbapenem-resistant Klebsiella pneumoniae infections a retrospective study. Front Pharmacol. 2021;12:780940. https://doi.org/10.3389/fphar.2021.780940

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, et al. Ceftazidime-Avibactam is Superior to Other Treatment regimens against Carbapenem-resistant Klebsiella pneumoniae Bacteremia. Antimicrob Agents Chemother. 2017;61(8). https://doi.org/10.1128/AAC.00883-17

Institute C. Performance standards for Antimicrobial susceptibility testing. United States: CLSI; 2020.

Google Scholar 

Satlin MJ, Lewis JS, Weinstein MP, Patel J, Humphries RM, Kahlmeter G, et al. Clinical and Laboratory Standards Institute and European Committee on Antimicrobial susceptibility testing position statements on Polymyxin B and Colistin Clinical breakpoints. Clin Infect Dis. 2020;71(9):e523. https://doi.org/10.1093/cid/ciaa121

Article  CAS  PubMed  Google Scholar 

Yan Y, Yang H, Pan L, Sun K, Fan H, Lu Y, et al. Improving the efficiency of the modified Hodge test in KPC-producing Klebsiella pneumoniae isolates by incorporating an EDTA disk. Curr Microbiol. 2014;69(1):47–52. https://doi.org/10.1007/s00284-014-0552-5

Article  CAS  PubMed  Google Scholar 

Doi Y, Potoski BA, Adams-Haduch JM, Sidjabat HE, Pasculle AW, Paterson DL. Simple disk-based method for detection of Klebsiella pneumoniae carbapenemase-type beta-lactamase by use of a boronic acid compound. J Clin Microbiol. 2008;46(12):4083–6. https://doi.org/10.1128/jcm.01408-08

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karaiskos I, Galani I, Papoutsaki V, Galani L, Giamarellou H. Carbapenemase producing Klebsiella pneumoniae: implication on future therapeutic strategies. Expert Rev Anti Infect Ther. 2022;20(1):53–69. https://doi.org/10.1080/14787210.2021.1935237

Article  CAS  PubMed  Google Scholar 

Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, et al. Efficacy and safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the treatment of complicated intra-abdominal infection: results from a Randomized, controlled, Double-Blind, phase 3 program. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2016;62(11):1380–9. https://doi.org/10.1093/cid/ciw133

Article  CAS  Google Scholar 

Torres A, Zhong N, Pachl J, Timsit JF, Kollef M, Chen Z, et al. Ceftazidime-Avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18(3):285–95. https://doi.org/10.1016/s1473-3099(17)30747-8

Article  CAS  PubMed  Google Scholar 

van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, et al. Colistin Versus Ceftazidime-Avibactam in the treatment of infections due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2018;66(2):163–71. https://doi.org/10.1093/cid/cix783

Article  Google Scholar 

Almangour TA, Ghonem L, Aljabri A, Alruwaili A, Al Musawa M, Damfu N et al. Ceftazidime-Avibactam versus Colistin for the treatment of infections due to Carbapenem-Resistant enterobacterales: a Multicenter Cohort Study. Infection and drug resistance. 2022;15:211–21https://doi.org/10.2147/idr.S349004

Chen Y, Huang HB, Peng JM, Weng L, Du B. Efficacy and safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Enterobacterales Bloodstream Infection: a systematic review and Meta-analysis. Microbiol Spectr. 2022;10(2):e0260321. https://doi.org/10.1128/spectrum.02603-21

Article  CAS  PubMed  Google Scholar 

Zhou J, Yang J, Hu F, Gao K, Sun J, Yang J. Clinical and Molecular Epidemiologic Characteristics of Ceftazidime/Avibactam-Resistant carbapenem-resistant Klebsiella pneumoniae in a neonatal intensive care unit in China. Infect Drug Resist. 2020;13:2571–8. https://doi.org/10.2147/IDR.S256922

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang P, Shi Q, Hu H, Hong B, Wu X, Du X et al. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China. Clin Microbiol Infect. 2020;26(1):124 ehttps://doi.org/10.1016/j.cmi.2019.08.020

Xiong L, Wang X, Wang Y, Yu W, Zhou Y, Chi X, et al. Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam. WIREs Mech Dis. 2022;e1571. https://doi.org/10.1002/wsbm.1571

Li X, Zhang J, Yang C, Li J, Wang J, Huang W, et al. Increased expression and amplification of blaKPC-2 contributes to resistance to Ceftazidime/Avibactam in a sequence type 11 Carbapenem-resistant Klebsiella pneumoniae strain. Microbiol Spectr. 2022;e0095522. https://doi.org/10.1128/spectrum.00955-22

Matlock A, Garcia JA, Moussavi K, Long B, Liang SY. Advances in novel antibiotics to treat multidrug-resistant gram-negative bacterial infections. Intern Emerg Med. 2021;16(8):2231–41. https://doi.org/10.1007/s11739-021-02749-1

Article  PubMed  PubMed Central  Google Scholar 

Balandín B, Ballesteros D, Pintado V, Soriano-Cuesta C, Cid-Tovar I, Sancho-González M, et al. Multicentre study of ceftazidime/avibactam for Gram-negative bacteria infections in critically ill patients. Int J Antimicrob Agents. 2022;59(3):106536. https://doi.org/10.1016/j.ijantimicag.2022.106536

Article  CAS  PubMed  Google Scholar 

Gu J, Xu J, Zuo TT, Chen YB. Ceftazidime-Avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae: ceftazidime-avibactam against CR-KP infections. J Global Antimicrob Resist. 2021;26:20–5. https://doi.org/10.1016/j.jgar.2021.04.022

Article  CAS  Google Scholar 

Zhang F, Zhong J, Ding H, Liao G. Efficacy of Ceftazidime-Avibactam in the treatment of Carbapenem-resistant Klebsiella pneumoniae infection after kidney transplantation. Infect Drug Resist. 2021;14:5165–74. https://doi.org/10.2147/IDR.S343505

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou C, Jin L, Wang Q, Wang X, Chen F, Gao Y et al. Bloodstream infections caused by Carbapenem-Resistant Enterobacterales: risk factors for Mortality, Antimicrobial Therapy and Treatment outcomes from a prospective Multicenter Study. Infection and drug resistance. 2021;14:731–42https://doi.org/10.2147/idr.S294282

Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the treatment of extended-spectrum β-lactamase Producing enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat Resistance (DTR-P. aeruginosa). Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2021;72(7):e169–83. https://doi.org/10.1093/cid/ciaa1478

Article  CAS  Google Scholar 

Busch LM, Kadri SS. Antimicrobial Treatment Duration in Sepsis and Serious infections. J Infect Dis. 2020;222(Suppl 2):S142–55. https://doi.org/10.1093/infdis/jiaa247

Article  CAS  PubMed  PubMed Central